Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Jensen Huangs acknowledged affair and Nvidias independent board investigation, prompted by reports linking the woman to suspected Chinese intelligence activity, drove concern about leadership stability and possible security risks. Traders debated whether the controversy could materially affect Nvidia or was a temporary distraction, with many viewing the share-price drop as a buying opportunity and others wary of further fallout.

A sharp pre-earnings rally ahead of TTDs Q3 report has traders debating whether hopes for a turnaround and possible short covering are driving the move; others remain cautious given concerns about slowing growth and weak guidance.

Jefferies Buy initiation and favorable Phase III prostate cancer data are drawing attention to Candels planned BLA filing for CAN-2409. Bulls see the results and recent immune-profile data as support for the regulatory case, while skeptics question filing execution, manufacturing readiness, financing needs and management transparency.

TG Therapeutics Q3 results and higher revenue outlook, driven by BRIUMVI growth, dominate discussion, but the shares sold off despite the positive report. Traders debate whether this is a sell-the-news reaction or short-driven pressure, while many point to Phase 3 data for subcutaneous BRIUMVI as the next major catalyst.

Hims is in focus ahead of its quarterly results as traders weigh the Eli Lilly agreement to offer branded obesity drugs through its platform against concerns that the shift could pressure margins. The sharp decline has fueled speculation about disappointing results or an earnings leak, while others see the partnership and potential growth as reasons to stay bullish.

Clover shares are drawing attention after a sharp, high-volume move above a closely watched resistance level, with traders focused on whether the breakout will hold. The move follows a quarterly earnings beat and improved full-year outlook, though investors disagree on the upside until Counterparts software business shows clearer external revenue.

BlackBerrys QNX ecosystem is drawing attention, especially its Valeo smart-camera platform with design wins at Chinese automakers and its Nvidia and robotics connections. Traders are upbeat about the recent share-price strength and buying activity, while skeptics question whether partnerships and backlog will translate into meaningful revenue and see the stock as range-bound.

IonQs stronger-than-expected quarterly results and raised full-year revenue outlook are driving attention, with traders also pointing to expanding backlog and quantum-computing demand. Bulls see evidence of commercial momentum, while skeptics question dilution, cash burn and how much growth came from the SkyWater acquisition, keeping the reaction volatile.

QXO is drawing attention after preliminary third-quarter results showed strong growth, largely reflecting its acquisitions, and CEO Brad Jacobs struck an upbeat tone on a conference call. Bulls welcomed the update as evidence the building-products roll-up is progressing, while some remain concerned about integration, dilution and the companys long-term strategy.

IBRX is selling off after Q3 revenue and earnings missed expectations, with the sequential revenue decline intensifying concerns about ANKTIVAs commercial ramp, cash burn and potential dilution; some traders also criticize managements lack of an earnings call. Bulls counter that ANKTIVA met the primary endpoint in a randomized bladder-cancer trial and won another international approval, viewing the selloff as an overreaction to near-term sales weakness.